Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06435312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Study acronym: ziMyG+
StatusEnrolling by Invitation
PhasePhase 3
Started2024-11-19
View on ClinicalTrials.gov ↗

Amendment history

2026-07-30
Study Status v17
Re-verified, no change to tracked fields
2026-07-02
Study Status, Contacts/Locations v16
Study sites7→6
2026-05-07
5 amendments v11-v15
5 re-verifications since 2026-03-12, no change to tracked fields
2026-02-26
Study Status, Contacts/Locations v10
Study sites8→7
2026-02-12
Study Status, Contacts/Locations v9
Study sites9→8
Show 8 earlier versions
2026-02-11
Study Status v8
Completion date2027-12-07→2027-11-19
2026-01-05
Study Status, Contacts/Locations v7
Study sitesdetails revised at 1 of 9 sites
2025-12-18
Study Status, Contacts/Locations v6
Study sitesdetails revised at 1 of 9 sites
2025-03-12
Study Status, Contacts/Locations v5
Study sites8→9
2025-02-13
Study Status, Contacts/Locations v4
Study sites5→8
2025-01-30
Study Identification, Study Status v3
Re-verified, no change to tracked fields
2024-12-02
Not Yet Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Enrolling by Invitation
Start dateestimated 2024-10-28→confirmed 2024-11-19
Study sites0→5
2024-08-14
Study Status v1
Start date2024-08-13→2024-10-28
2024-05-23
Original filing
The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants
Trial Details
NCT Number NCT06435312
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 8 participants
Start Date 2024-11-19
Primary Completion 2027-10-26 (estimated)
Study Completion 2027-11-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-31